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Fig. S1. Band area feature. Fig. S2 . Estimation of the LoD using a linear regression. Fig. S3 . Analysis of the validity of calibration using the background subtraction method used in Fig. 1A and the LoD measurement. Fig. S4 . Change in glucose concentration measured by a YSI glucose analyzer and Accu-Chek finger-prickers (top panels) and vital signs from the subject. 5C ). Using the above LoD definition with minimal glucose concentrations around 52 mg/dL, the LoD of our measurements was calculated as ~75 mg/dL. It is noted that the standard deviation was calculated with the datasets nearest to zero concentration. Pearson correlation coefficient between the subtraction spectra and the spectrum of pure glucose in solution. This demonstrates high correlation coefficients for ~ 50 min when enough differences started to appear in the corresponding glucose concentrations between subtraction spectra. The initial low correlations were due to the small glucose change from the approximately flat glucose level. This indicates that the calibration using the subtraction reference spectrum can stay valid and reliable for ~ 50 min. (E) The squared Pearson correlation coefficients as a function of glucose concentration difference, combining the results in panels C and D. For glucose concentration differences smaller than ~ 30 mg/dL (marked as blue dots), glucose signal differences in the corresponding subtraction spectra were observed to be buried below the noise level. At the glucose concentration difference of 78 mg/dL (a red dot), a distinguishing correlation coefficient from the prior data started to appear (the same color codes were applied in panels B to E.). The unfilled gap with data between 30 mg/dL and 78 mg/dL was due to the limited number of datasets from our in vivo experiment.
Fig. S4. Change in glucose concentration measured by a YSI glucose analyzer and Accu-
Chek finger-prickers (top panels) and vital signs from the subject. Trials 1 to 3 in Panels A to C, respectively. The vital signs include the subject's body temperature, end-tidal CO 2 (ET CO2), respiration rate (RR), heart rate (HR), and blood oxygen saturation (SPO2). Non-sequential ray-tracing simulation to confirm the performance of the designed Raman probe. It should be noted that a different design for Raman probe was used for the Trial 2. Instead of using 2 mm-diameter fiber-bundle directly over the sampling volume for collection of Raman photons, a simple imaging type Raman probe with lenses were used for higher NA collection from skin. The magnification of the probe is set to match the diameter of the 1.95 mm-diameter input aperture of the fiber-bundle. Linearity between G vs. I. Linearity of the Raman peak to glucose concentration becomes poor for the entire recordings (R=0.74), though two partial time-continuous recordings show great linearity (R=0.96 with data points both in cyan color in the first one third recordings and R=0.97 with those in magenta color in the last two thirds.). The broken linearity is considered to occur due to the subject's movement. (C) The corresponding band-area ratio vs. glucose concentration. Panel C shows the improved linearity in the entire recordings as R=0.94. This confirms the effectiveness of the suggested band-area feature for blood-glucose prediction.
